Unraveling the impact of 27-hydroxycholesterol in autoimmune diseases: Exploring promising therapeutic approaches.

Ahmed Hjazi, Maria Ahsan, Mohammed I Alghamdi, A K Kareem, Dahlia N Al-Saidi, Maytham T Qasim, Rosario Mireya Romero-Parra, Rahman S Zabibah, Andrés Alexis Ramírez-Coronel, Yasser Fakri Mustafa, Seyed Reza Hosseini-Fard, Sajad Karampoor, Rasoul Mirzaei

Journal: Pathology, research and practice 2023;248():154737

PMID: 37542860

Full Text on Elsevier Science View on PubMed

Abstract

The role of 27-hydroxycholesterol (27-OHC) in autoimmune diseases has become a subject of intense research in recent years. This oxysterol, derived from cholesterol, has been identified as a significant player in modulating immune responses and inflammation. Its involvement in autoimmune pathogenesis has drawn attention to its potential as a therapeutic target for managing autoimmune disorders effectively. 27-OHC, an oxysterol derived from cholesterol, has emerged as a key player in modulating immune responses and inflammatory processes. It exerts its effects through various mechanisms, including activation of nuclear receptors, interaction with immune cells, and modulation of neuroinflammation. Additionally, 27-OHC has been implicated in the dysregulation of lipid metabolism, neurotoxicity, and blood-brain barrier (BBB) disruption. Understanding the intricate interplay between 27-OHC and autoimmune diseases, particularly neurodegenerative disorders, holds promise for developing targeted therapeutic strategies. Additionally, emerging evidence suggests that 27-OHC may interact with specific receptors and transcription factors, thus influencing gene expression and cellular processes in autoimmune disorders. Understanding the intricate mechanisms by which 27-OHC influences immune dysregulation and tissue damage in autoimmune diseases is crucial for developing targeted therapeutic interventions. Further investigations into the molecular pathways and signaling networks involving 27-OHC are warranted to unravel its full potential as a therapeutic target in autoimmune diseases, thereby offering new avenues for disease intervention and management.

Address: Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.; King Edward Medical University Lahore, Pakistan.; Department of Computer Science, Al-Baha University, Al-Baha City, Kingdom of Saudi Arabia.; Biomedical Engineering Department, Al-Mustaqbal University College, Babylon, Iraq.; Department of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq.; Department of Anesthesia, College of Health and Medical Technology, Al-Ayen University, Thi-Qar, Iraq.; Department of General Studies, Universidad Continental, Lima, Perú.; Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq.; Health and Behavior Research Group (HBR), Psychometry and Ethology Laboratory, Catholic University of Cuenca, Ecuador; University of Palermo, Buenos Aires, Argentina; Research group in educational statistics, National University of Education, Azogues, Ecuador; Epidemiology and Biostatistics Research Group, CES University, Colombia.; Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul 41001, Iraq.; Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: [email protected].; Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran. Electronic address: [email protected].; Venom and Biotherapeutics Molecules Lab, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. Electronic address: [email protected].

DOI: 10.1016/j.prp.2023.154737

Link outs

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0344...

MeSH Terms: Humans, Hydroxycholesterols, Cholesterol, Oxysterols, Transcription Factors